A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using ¹⁸F-FES PET/CT imaging.

ABSTRACT:

Background

Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmenopausal women with ER+ advanced breast cancer (ABC) using 16α-¹⁸F-fluoro-17β-estradiol positron emission tomography with low-dose computed tomography (FES-PET/CT).

Methods

Eligible patients were postmenopausal women with ER+, HER2- ABC; tumor progression after ≥ 6 months of 1-3 lines of endocrine treatment for ABC; and measurable or evaluable disease. Two 8-patient cohorts were enrolled: one treated with 400 mg elacestrant once daily (QD) and one treated with 200 mg elacestrant QD with dose escalation to 400 mg QD after 14 days.

SUBMITTER: Jager A 

PROVIDER: S-EPMC7488419 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature